DGX·Quest Diagnostics Incorporated
DGX|Analyst Targets
DGX|Company Info
DGX|Insider Trading
DGX|Fundamentals
DGX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.87 | - | - |
| Q2'26 | $2.82 | $3.12 | +10.5% |
| Q1'26 | $2.37 | $2.50 | +5.6% |
| Q4'25 | $2.45 | $2.42 | -1.4% |
| Q3'25 | $2.50 | $2.60 | +3.9% |
| Q2'25 | $2.57 | $2.62 | +1.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.1B | - | - |
| Q2'26 | $3.0B | $3.0B | +1.3% |
| Q1'26 | $2.8B | $2.9B | +2.4% |
| Q4'25 | $2.8B | $2.8B | +0.9% |
| Q3'25 | - | $2.8B | - |
| Q2'25 | - | $2.8B | - |
DGX|Monthly Returns
Market Data
DGX Stock Snapshot
- Market cap
- 25.61B
- P/E ratio
- 24.1
- Day range
- $231.32 – $234.97
- News sentiment
- 57/100 · Neutral
- Analyst target
- $248.80 (+6.6%)
- Consensus
- Hold · 25 analysts
DGX's technical picture is constructive, with trend and momentum pointing the same direction. Earnings and guidance carry more weight than macro data at this capitalisation.
Reverse DCF
What growth is priced into DGX?
At today's price, Quest Diagnostics Incorporated needs to grow free cash flow about 2.4% a year for the next 10 years to justify its valuation at a 7.03% cost of capital. Over its actual history it has compounded free cash flow at 3.3% a year, so the market is asking for 0.9 percentage points below its own delivered rate. On that basis DGX looks priced roughly in line with its own growth record.
- Implied FCF growth
- 2.4%
- Historical FCF CAGR
- 3.3%
- Growth gap
- -0.9 pts
- Verdict
- FAIR
- Discount rate (WACC)
- 7.03%
- Beta
- 0.44
Behaviour On Record
What DGX's own history says about today's numbers
- Realized volatility (21d)
- 31.0% 90th pct
- Below its peak
- -5.7%
- vs 200-day average
- +12.3%
- Up days (1y)
- 49%
Quest Diagnostics Incorporated is currently running 31.0% annualised volatility over the last 21 sessions. Measured against DGX's own 13 years of daily returns rather than a market-wide average, that is the 90th percentile — elevated for this stock, against a typical reading of 19.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
DGX is trading -5.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.9%, and the deepest was -39.3% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +12.3% from its 200-day moving average. Against every other day in its history, that gap ranks at the 83rd percentile — a wider gap than this stock usually carries. Over the past year DGX closed higher on 49% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 14 years of records, DGX finished the month higher 10 of 14 times, with a median return of +1.7% and an average of +2.1%. Its strongest month historically has been April at +4.1% on average, its weakest September at -1.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: DGX has opened more than 2% away from the prior close in 72 of 3,268 sessions (2.2% of the time), with the largest gaps running +6.4% and -9.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, DGX moved an average of 1.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.2% and a largest of -2.5%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against DGX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of DGX's sector?
Quest Diagnostics Incorporated sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on DGX?
Barclays most recently reiterated its rating on Quest Diagnostics Incorporated to Overweight on Oct 7, 2026 with a price target of $260 (from $250). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Barclays — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
DGX peers & ETF holders
Diagnostics & ResearchMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 14,392,082 | 12.95% | $2.50B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 9,275,411 | 8.35% | $1.97B | 2026-08-07 |
| JPMorgan Chase & Co | ▼ Sell | 3,520,438 | 3.17% | $748.59M | 2026-08-12 |
| Geode Capital Management, LLC | ▲ Buy | 3,137,873 | 2.82% | $662.58M | 2026-08-12 |
| Morgan Stanley | ▼ Sell | 2,460,497 | 2.21% | $521.50M | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 1,935,133 | 1.74% | $410.15M | 2026-08-14 |
| Wells Fargo & Company | ▼ Sell | 1,751,220 | 1.58% | $371.17M | 2026-08-14 |
| Davis Selected Advisers | ▼ Sell | 1,555,612 | 1.40% | $329.78M | 2026-08-11 |
| Norges Bank | ▲ Buy | 1,406,620 | 1.27% | $298.13M | 2026-08-12 |
| FMR LLC (Fidelity) | ▲ Buy | 1,398,735 | 1.26% | $296.46M | 2026-08-13 |
| Invesco Ltd. | ▼ Sell | 1,379,115 | 1.24% | $292.30M | 2026-08-14 |
| Northern Trust Corp | ▲ Buy | 1,127,454 | 1.01% | $238.96M | 2026-08-13 |
| Goldman Sachs Group Inc | ▼ Sell | 982,694 | 0.88% | $208.28M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 625,894 | 0.56% | $122.66M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 315,584 | 0.28% | $66.89M | 2026-08-03 |
| Balyasny Asset Management L.P. | ▲ Buy | 275,371 | 0.25% | $58.36M | 2026-08-14 |
| Marshall Wace, LLP | ▲ Buy | 269,760 | 0.24% | $57.18M | 2026-08-13 |
| Citadel Advisors LLC | ▼ Sell | 133,211 | 0.12% | $28.23M | 2026-09-02 |
| Squarepoint Ops LLC | ▼ Sell | 117,831 | 0.11% | $24.97M | 2026-08-14 |
| Gotham Asset Management, LLC | ▼ Sell | 117,533 | 0.11% | $24.91M | 2026-08-14 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 106,303 | 0.10% | $22.53M | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 87,570 | 0.08% | $18.56M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 61,196 | 0.06% | $12.92M | 2026-08-14 |
| Prudential Financial Inc | ▲ Buy | 60,134 | 0.05% | $12.75M | 2026-08-12 |
| Neuberger Berman Group LLC | ▲ Buy | 53,224 | 0.05% | $11.28M | 2026-08-13 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-30 | 2026-07-21 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-03 | 2025-12-11 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-10-30 | 2026-08-05 |
| Julie Johnson | House | TX32 | ▲ Buy | $1K - $15K | 2025-10-30 | 2026-08-05 |
| Julia Letlow | House | LA05 | ▼ Sell | $1K - $15K | 2025-07-24 | 2026-01-13 |
| Julia Letlow | House | LA05 | ▲ Buy | $1K - $15K | 2025-04-28 | 2026-01-13 |
| Carol Devine Miller | House | WV01 | ▼ Sell | $15K - $50K | 2025-03-10 | 2026-08-13 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $15K - $50K | 2024-01-03 | 2024-02-14 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2021-03-29 | 2021-07-23 |